A5083001171- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Acute Myeloid Leukemia Research
- Eosinophilic Disorders and Syndromes
- Protein Degradation and Inhibitors
- Kruppel-like factors research
- Multiple Myeloma Research and Treatments
- CNS Lymphoma Diagnosis and Treatment
- Lymphoma Diagnosis and Treatment
- Protein Tyrosine Phosphatases
- Chronic Myeloid Leukemia Treatments
- CAR-T cell therapy research
- Viral-associated cancers and disorders
- Histone Deacetylase Inhibitors Research
- Multiple and Secondary Primary Cancers
- Cancer Genomics and Diagnostics
- Acute Lymphoblastic Leukemia research
- Research on Leishmaniasis Studies
- Genomics, phytochemicals, and oxidative stress
University of South Florida
2020-2024
Moffitt Cancer Center
2019-2024
Myeloproliferative neoplasms (MPNs), including polycythemia vera, essential thrombocytosis, and primary myelofibrosis, are clonal hematopoietic driven by mutationally activated signaling the JAK2 tyrosine kinase. Although inhibitors can improve MPN patients' quality of life, they do not induce complete remission as disease-driving cells persistently survive therapy. ERK activation has been highlighted contributing to inhibitor persistent cell survival. As is a component RAS proteins...
Extranodal marginal zone lymphoma (EMZL) encompasses 70% of cases lymphoma. Frontline bendamustine and rituximab (BR) were derived from trials involving other indolent non-Hodgkin's lymphomas. Only one trial has evaluated frontline BR prospectively in EMZL. This retrospective study reports outcomes among EMZL patients receiving BR. Twenty-five included with a median age 69 years (40-81). Five (20.0%) had stage I/II disease, 20 (80.0%) III/IV disease. The number cycles was 6.0 (3.0-6.0)....
Mixed phenotype acute leukemia (MPAL) is a rare group of leukemias with blasts that co-express antigens more than one lineage or separate populations different lineages. Though treatment guidelines are not well established, the standard care in treating MPAL remains lymphoblastic (ALL)-derived chemotherapeutic regimen hyper-cyclophosphamide, vincristine, doxorubicin (also known by its trade name, Adriamycin), and dexamethasone (CVAD) followed allogeneic stem-cell transplant (ASCT). Beyond...
e19010 Background: Recent studies showed that IDH1/2 are frequently mutated in AML and aberrant 2-HG elevation driven by the mutant proteins plays a pivotal role development. Subsequent clinical trials of inhibitors demonstrated promising outcomes mut patients. In this single institutional retrospective study, we explored efficacy safety patients treated with Ivosidenib or Enasidenib. Methods: We retrospectively identified who had somatic mutations based on NGS assessments. Clinical...